Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses (TK-Onko)

June 1, 2023 updated by: Andreas Michalsen, Charite University, Berlin, Germany

Integrative Oncology - Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses

The aim of this study is to investigate the effects of a nature-centred integrative oncology day care unit programme ("outdoor concept") compared with an already established integrative oncology day care unit programme ("indoor concept").

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
107

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Berlin, Germany, 14109
        • Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

- cancer diagnosis

Exclusion Criteria:

  • cognitive impairment that would interfere with questionnaire replies or the intervention
  • pregnancy or lactation
  • known serious mental illness
  • participation in another study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Outdoor
Nature-centered therapy in a near-natural area
Behavioral: Nature-near integrative day care unit programme
Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
Active Comparator: Indoor
Conventional therapy in rooms mainly in a hospital building
Behavioral: Conventional integrative day care unit programme
Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Functional Assessment of Cancer Therapy - General (FACT-G)
Time Frame: Change from date of inclusion (baseline) at 12 weeks and at 24 weeks
Assessing full scale, range 0-108, higher score meaning a better outcome
Change from date of inclusion (baseline) at 12 weeks and at 24 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-40, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Functional Assessment of Cancer Therapy: Fatigue (FACT-F)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-52, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
WHO-Five Well-Being Index (WHO-5)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-25, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Perceived Benefits of Nature Questionnaire (PBNQ)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
mean score of the 11 items, range 1-7, lower score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Perceived Stress Scale (PSS-10)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-40, lower score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Hospital Anxiety and Depression Scale (HADS)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-42, lower score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Insomnia Severity Index (ISI)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-28, lower score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Self-Compassion Scale (SCS-D)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
mean score of 12 items, range 1-5, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Behavioral questions: alcohol consumption
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Number of alcoholic beverages on average per week in the last month
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Behavioral questions: relaxation
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Relaxation behavior on average per week in the last month in minutes
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Behavioral questions: cigarettes
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Number of cigarettes on average per week in the last month in minutes
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Sociodemographic Measurements
Time Frame: Date of inclusion (baseline)
Age, gender, education level, household income, employment status, marital status, complete family history, current and previous diseases and co-morbidities, current medication intake
Date of inclusion (baseline)
Body weight
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
kg
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Expectation questions
Time Frame: Date of inclusion (baseline)
For intervention 1 and intervention 2 on a 5-point likert scale from 1 (nothing at all) to 5 (very strong)
Date of inclusion (baseline)
Behavioral questions: sport
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Sports behavior on average per week in the last month in minutes
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Flourishing Scale (FS-D)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 8-56, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Freiburg Mindfulness Inventory (FMI)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
Assessing full scale, range 0-56, higher score meaning a better outcome
Date of inclusion (baseline), after 12 weeks, after 24 weeks
Self-Efficacy Scale - Short Form (ASKU)
Time Frame: Date of inclusion (baseline), after 12 weeks, after 24 weeks
mean score of the 3 items, range 1-5
Date of inclusion (baseline), after 12 weeks, after 24 weeks

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Qualitative interviews
Time Frame: 12 weeks and 24 weeks after inclusion
Qualitative assessment will be carried out in qualitative interviews in 20 patients participating in the study. The interviews will be recorded, transcribed and analyzed with qualitative content analysis.
12 weeks and 24 weeks after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Charite University, Berlin, Germany

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 14, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 25, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 28, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 2, 2020

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 2, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 1, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • TK-Onko

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings